United States Adhesion Barrier Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Adhesion Barrier Market Trends and Insights

Rising Robotic and Minimally Invasive Surgery Volumes

Robotic surgery is expanding the procedural base that can support faster adoption in the United States adhesion barrier market. Robotic-assisted procedures now account for 22% of all surgeries performed in the United States, and adoption remains strongest in major hospital systems that continue to deploy newer platforms. This shift matters because much of the installed product base in the United States adhesion barrier market still centers on rigid film formats that fit open surgery better than trocar-based access. As a result, the growth of robotic and minimally invasive surgery is pushing the United States adhesion barrier market toward gels, sprays, and other conformable products that can be delivered through smaller ports and over uneven tissue surfaces. The stronger the shift toward these procedures, the more the United States adhesion barrier market rewards developers that can reduce handling friction in laparoscopic and robotic settings.^{[1]FzioMed, “FzioMed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex Gel in Spine Surgery,” FzioMed, fziomed.com} That format transition is already visible in the faster expected growth rate of gels compared with the overall category. 

Bundled Payment Pressure to Reduce Adhesion-Related Readmissions

Bundled payment reform is making complication avoidance more financially relevant in the United States adhesion barrier market. CMS finalized the TEAM model with mandatory implementation starting January 1, 2026, across 741 hospitals in 188 metropolitan statistical areas, and the covered episodes include major bowel procedures and spinal fusion. These episodes matter because adhesions affect up to 93% of patients after abdominal or pelvic surgery, while open surgery and colorectal surgery are associated with much higher readmission risk from adhesion-related complications.^{[2]American College of Surgeons, “Surgical Adhesions Improvement Project Advances Disease Science,” ACS Bulletin, facs.org} Readmissions also feed directly into the quality and repayment logic of TEAM, which gives hospital administrators a clearer basis for evaluating prevention tools in the United States adhesion barrier market. CMS has also shortened the HRRP measurement window from 3 years to 2 years for FY2026, which makes recent performance more visible and raises the cost of preventable readmission events. Together, these payment changes are moving the United States adhesion barrier market closer to a risk-management purchase decision instead of a purely discretionary clinical add-on.

Product Innovation in Bioresorbable and Sprayable Barriers

Product innovation is changing where growth will come from in the United States adhesion barrier market. In July 2025, the FDA granted De Novo classification and marketing authorization for Oxiplex gel, which became the first FDA-authorized intraoperative gel designed for lumbar spine procedures with a specific postoperative clinical purpose. Research teams are also advancing sprayable hydrogel systems that form a protective coating within seconds through endoscopic delivery, which directly addresses the access problem that limited older open-surgery products. Peer-reviewed work continues to show that currently approved products do not perform equally well across all tissue types and surgical fields, so the clinical need is not limited to a new format alone. This creates room in the United States adhesion barrier market for products that combine easier delivery with more predictable tissue performance and degradation behavior. The companies that can bring those qualities into routine operating room use are positioned to capture the most attractive adoption pool in the United States adhesion barrier market.

Expansion of Ambulatory Surgical Centers in the United States

ASC expansion is opening a new volume channel for the United States adhesion barrier market. As of Q2 2025, the United States had 12,294 ASCs, including 6,504 Medicare-certified facilities, and CMS certified 168 new facilities in 2024 alone.^{[3]ASC Data, “ASC Data Industry Overview,” ASC Data, ascdata.com} Procedure volume per Medicare fee-for-service beneficiary at ASCs rose 3.5% in 2024, and total fee-for-service Medicare spending on ASC services reached USD 7.5 billion in the same year. That migration favors product formats that are easy to deliver, easy to store, and easier to justify on a per-case basis than film-heavy solutions. The same shift supports the faster role of gel and sprayable systems in the United States adhesion barrier market because outpatient centers are seeing more laparoscopic gynecological, orthopedic, and general surgery cases. The more procedures move into ASCs, the more the United States adhesion barrier market depends on products that fit outpatient economics and shorter workflow cycles. This is why channel growth and format innovation are now moving together rather than as separate trends.

Uneven Reimbursement Recognition Across Procedure Settings

Reimbursement remains one of the clearest limits on adoption in the United States adhesion barrier market. CMS recognizes adhesion barriers under HCPCS Level II code C1765, but payment treatment still varies by payer, procedure, and site of care, and many ASC and outpatient settings must absorb the cost within existing facility fees. That gap is especially relevant for gynecological and minimally invasive procedures because those cases are moving into settings where margins are tighter and product-specific payment support is less consistent. The pressure is stronger in 2026 because HRRP changes broaden the readmission measurement base while not creating a uniform reimbursement pathway for adhesion prevention products. Clinical guidance supports use in selected settings, but endorsement alone has not converted into consistent coding and payment treatment across the United States adhesion barrier market. Until that changes, many facilities will continue to weigh barrier use against immediate case economics instead of total complication costs over the full episode of care.

Surgeons' Preference for Technique-Only Adhesion Prevention

Surgeon behavior still slows broader penetration in the United States adhesion barrier market. Recent reporting showed that fewer than 15% of surgeons used an adhesion barrier product within the last year, which indicates that procedural habit remains a major barrier even when clinical need is well recognized. Part of this reluctance reflects confidence in meticulous technique alone, and part of it reflects product handling limits in minimally invasive procedures where conventional films are difficult to use. The preference is also reinforced when surgeons see variability in performance across tissue types or surgical fields, because inconsistent outcomes make routine use harder to justify. This means growth in the United States adhesion barrier market depends not only on product approval, but also on better workflow fit, clearer procedure-specific evidence, and more surgeon training in delivery technique. Products that simplify application are more likely to reduce this behavioral barrier over time.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Synthetic Platforms Anchor Share as Natural Barrier Biocompatibility Gains Traction

Synthetic products held 53.48% of United States adhesion barrier market share in 2025, which made them the largest product type in the category. Their lead reflects long-standing use in hospital operating rooms, broad familiarity among surgical teams, and the presence of established FDA-cleared platforms. Hyaluronic acid and regenerated cellulose variants remain central within this segment, while polyethylene glycol systems are gaining relevance in neurological and cardiovascular use where conformable coverage is important. Natural barriers are projected to grow at a 7.36% CAGR through 2031, which makes them the fastest-growing product type in the United States adhesion barrier market. 

That faster growth reflects interest in collagen and fibrin materials that align with a tissue-mimicking profile and lower local inflammatory response. Peer-reviewed research on postoperative adhesions continues to support the value of bioresorbable chemistries derived from endogenous or biologically familiar molecules such as chondroitin sulfate, hyaluronic acid, and fibrin. The FDA pathway used for Oxiplex also shows that novel formulations can still enter the US adhesion barrier industry when they are supported by procedure-specific evidence and clear device controls. As hospital sourcing shifts toward biocompatibility and differentiated outcomes, companies with both synthetic depth and natural material exposure should be better placed in the United States adhesion barrier market.

By Formulation: Film and Mesh Lead Volume While Gel Formats Target Minimally Invasive Access

Film and mesh formulations accounted for 44.17% of the United States adhesion barrier market size in 2025, which kept them in the leading position by formulation. Their strength remains tied to open abdominal, pelvic, and gynecological procedures where placement over exposed tissue is straightforward and familiar. Baxter’s Seprafilm continues to represent the best-known commercial architecture in this part of the United States adhesion barrier market and is supported by broad clinical familiarity. Even so, this format is structurally less suited to laparoscopic and robotic delivery than newer gel and spray approaches.

Gel formulations are forecast to grow at an 8.87% CAGR through 2031, which is the fastest pace among all formulation types. That growth comes from better compatibility with minimally invasive access and from the ability to conform to irregular tissue surfaces that rigid films may not cover well. Research on sprayable hydrogels also shows that liquid and near-liquid delivery systems could widen the format mix further if they move from laboratory work into clinical use. The gap between film leadership and gel growth shows that the United States adhesion barrier industry is shifting from familiarity-led selection toward access-compatible selection.

By Absorbability: Absorbable Variants Retain Dominance as Non-Absorbable Platforms Address Durable-Barrier Demand

Absorbable barriers captured 88.42% share in 2025, which was the most concentrated split across the major segmentation types. This dominance reflects a clear clinical preference for products that resolve without requiring retrieval and that fit the single-intervention logic preferred by hospital teams. The segment also aligns with patient outcome priorities because it reduces long-term foreign-body concerns and limits the need for follow-up intervention. For the present revenue base of the United States adhesion barrier market, absorbable formats therefore remain the default choice across most established procedures.

Non-absorbable barriers are projected to grow at a 7.97% CAGR through 2031, even though they remain much smaller in absolute terms. Their growth points to durable demand in select cardiovascular and neurological procedures where longer physical separation is preferred to short-term degradation. The pattern suggests that the United States adhesion barrier market is not moving away from absorbability as a core principle, but is opening more room for procedure-led exceptions. Peer-reviewed literature also notes that performance can vary across tissue environments, which supports ongoing work on better degradation profiles and more targeted material behavior. That balance between broad absorbable use and niche durable use is likely to remain a stable feature of the United States adhesion barrier market.

By Application: Abdominal Surgery Leads Demand While Gynecological Procedures Drive the Next Growth Wave

General and abdominal surgeries held 35.62% of the United States adhesion barrier market size in 2025, which made them the largest application area. Their leadership comes from high adhesion incidence in abdominal and pelvic surgery and from the heavier complication burden tied to open colorectal procedures. Adhesions can affect up to 93% of patients after abdominal or pelvic surgery, and colorectal surgery carries a sharply elevated readmission hazard for adhesion-related complications. This keeps abdominal use central to the current revenue structure of the United States adhesion barrier market.

Gynecological surgeries are forecast to expand at an 8.23% CAGR through 2031, which makes them the fastest-growing application in the United States adhesion barrier market. Growth is being supported by rising laparoscopic gynecological case volume and by stronger protocol use in fertility-preserving surgery. Expert consensus published in 2024 also supported adhesion barrier use in gynecologic surgeries and cesarean section settings, which strengthens the clinical basis for broader uptake. Spine surgery adds another focused opportunity, as FzioMed’s Oxiplex gel entered the market with a specific neurological use profile rather than a broad, undifferentiated claim. The application mix therefore favors companies that can prove value procedure by procedure instead of relying on a single general positioning story.

By End User: Hospitals Anchor the Market While Ambulatory Surgical Centers Define the Growth Vector

Hospitals held 76.23% share of end-user demand in 2025, which kept them at the center of current purchasing in the United States adhesion barrier market. Their lead reflects concentration in open surgery, more complex abdominal cases, and higher-acuity cardiovascular and neurological procedures where evidence is stronger, and procurement systems are formalized. This structure also favors incumbent suppliers because formulary decisions in hospitals tend to reward clinical familiarity, documentation quality, and established vendor relationships. For these reasons, hospitals continue to define the present revenue base and pricing environment of the United States adhesion barrier market.

ASCs are projected to grow at a 7.35% CAGR through 2031, which makes them the fastest-growing end-user segment. The United States had 12,294 ASCs as of Q2 2025, including 6,504 Medicare-certified facilities, and that expanding base is shifting more laparoscopic and outpatient cases into settings that need simpler delivery formats. ASC purchasing also differs from hospital purchasing because physician-owner groups tend to focus more directly on per-case economics and workflow efficiency. That means companies serving the United States adhesion barrier industry need a different commercial approach for ASCs than for large hospital systems.

Geography Analysis

California, Florida, and Texas together accounted for nearly one-third of the Medicare-certified ASC base in 2025, which gives them outsized influence over procedure flow linked to the United States adhesion barrier market. California led with 917 Medicare-certified ASCs, followed by Florida with 531 and Texas with 505. These states combine large outpatient footprints with dense concentrations of hospital systems and specialist surgery groups. California also benefits from strong robotic surgery adoption in metropolitan and academic centers, which supports the shift toward products suited for minimally invasive workflows. This makes the Pacific and Sun Belt states especially relevant to the next phase of the United States adhesion barrier market.

Florida represents a distinct demand pattern because its older patient base and high procedure intensity increase exposure to abdominal, colorectal, orthopedic, and spinal episodes that fall within hospital readmission and bundled payment scrutiny. TEAM now covers 741 hospitals across 188 metropolitan statistical areas, and that concentration of financial accountability is most material in dense, high-utilization metro areas. Texas adds a large commercially insured population, a growing outpatient surgical footprint, and major academic medical centers that continue to shape robotic and complex surgery volumes. Fee-for-service Medicare spending on ASC services reached USD 7.5 billion in 2024, which shows how large the outpatient surgical base has become in regions where these states play a major role. 

Rural and smaller metro areas remain the harder part of the geographic picture for the United States adhesion barrier market. As of Q4 2025, 94% of ASCs were located in urban areas, which leaves many lower-density regions more dependent on community hospital operating rooms. Those hospitals often face tighter budget limits and lower case concentration, which makes premium adoption slower even when the clinical need exists. The ACS has also highlighted that education and transition support will matter across a broad range of hospital settings as adhesion prevention moves into a more financially accountable care environment.